Protalix Biotherapeutics (PLX)
XASE:PLX
Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.32
-$0.05(-2.01%)
At close: 4:00 PM EST
$2.32
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.32 - $3.19
Previous CloseN/A
Volume368.29K
Average Volume (3M)811.66K
Market Cap
$165.98M
Enterprise Value$129.52M
Total Cash (Recent Filing)$51.79M
Total Debt (Recent Filing)$8.48M
Price to Earnings (P/E)10.5
Beta0.69
Next Earnings
Aug 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding80,571,640
10 Day Avg. Volume551,403
30 Day Avg. Volume811,665
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda5.80
Forecast
1Y Price Target
$12.00Price Target Upside417.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$78.30M
Bulls Say, Bears Say
Bulls Say
Improved Margins & FCFA sustained step-up in gross and net margins alongside positive trailing‑12‑month free cash flow indicates the business can convert incremental revenue into cash. This strengthens the firm's ability to fund operations and trials internally and reduces near‑term financing dependence over the next 2–6 months.
Strong Cash & Low LeverageA milestone‑backed cash balance of $51M combined with no debt materially improves financial flexibility. That liquidity supports commercial rollout, PRX‑115 enrollment, and higher R&D spend without immediate dilutive financing, making near‑term execution less capital constrained.
Regulatory Approval Expands Product PropositionAn extended‑interval dosing approval reduces treatment burden — a durable clinical differentiation that can drive payer and patient preference. Structural adoption across jurisdictions supports sustainable market penetration and recurring revenue potential if reimbursement follows.
Bears Say
Historic Earnings & Cash VolatilityMaterial swings between loss years and profitable periods indicate inconsistent underlying operating performance. That volatility reduces confidence in the durability of margins and cash conversion, raising execution risk for sustaining growth and funding multi‑year programs without reliance on milestones.
Partner Demand Concentration RiskSignificant reliance on partner purchasing patterns makes core product revenue lumpy; inventory and timing decisions by large partners can materially reduce near‑term sales. This concentration risk can persist and hinder steady top‑line growth absent broader commercialization or diversified revenue streams.
Reimbursement & Trial Timing UncertaintyCommercial realization hinges on staggered national reimbursements and partner rollout, while clinical enrollment pace for PRX‑115 is uncertain. These timing risks can delay durable revenue recognition and extend cash burn, pressuring execution timelines and long‑term planning.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.32 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $165.98M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 60 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on May 13, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.23.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.01.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.22 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (417.24% Upside)
$12.00 (417.24% Upside)
Blogger Sentiment
Neutral
PLX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.05%
12-Months-Change
Fundamentals
Return on Equity
28.10%
Trailing 12-Months
Asset Growth
38.49%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins. The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease. Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases. The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.
PLX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive financial and operational picture driven by a $25 million milestone that produced Q1 profitability and strengthened the balance sheet to $51 million in cash. Management reaffirmed 2026 guidance and highlighted commercial and regulatory progress for Elfabrio and continued advancement of the PRX-115 program. Offsetting risks include a notable decline in product sales quarter-over-quarter (-26% in selling goods), increased R&D spend (+54%), and timing/visibility uncertainties tied to Chiesi reimbursement rollouts and trial enrollment pace. Overall, the positives (milestone, cash position, profitability, reaffirmed guidance, and clinical progress) materially outweigh the near-term revenue timing and expense increases.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(417.24% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.87% Insiders
2.71% Mutual Funds
6.20% Other Institutional Investors
82.93% Public Companies and
Individual Investors